vs
美国运通（AXP）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是美国运通的1.6倍（$30.3M vs $18.9M），美国运通净利率更高（15.7% vs -221.3%，领先237.1%），REGENXBIO Inc.同比增速更快（43.0% vs 11.4%），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -95.6%）
美国运通是全球知名的支付服务提供商，主营签账卡、信用卡产品及旅行相关服务，下设全球消费者服务、全球商业服务、全球商户与网络服务三大业务板块，还提供支付融资、网络服务、应付账款费用管理、旅行生活服务等多元解决方案。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
AXP vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.6倍
$18.9M
营收增速更快
RGNX
高出31.6%
11.4%
净利率更高
AXP
高出237.1%
-221.3%
两年增速更快
RGNX
近两年复合增速
-95.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.9M | $30.3M |
| 净利润 | $3.0M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | — | -190.0% |
| 净利率 | 15.7% | -221.3% |
| 营收同比 | 11.4% | 43.0% |
| 净利润同比 | 15.0% | -31.2% |
| 每股收益（稀释后） | — | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AXPRGNX
| Q1 26 | $18.9M | — | ||
| Q4 25 | $10.9B | $30.3M | ||
| Q3 25 | $10.4B | $29.7M | ||
| Q2 25 | $10.3B | $21.4M | ||
| Q1 25 | $9.6B | $89.0M | ||
| Q4 24 | $10.0B | $21.2M | ||
| Q3 24 | $9.7B | $24.2M | ||
| Q2 24 | $9.8B | $22.3M |
净利润AXPRGNX
| Q1 26 | $3.0M | — | ||
| Q4 25 | $2.5B | $-67.1M | ||
| Q3 25 | $2.9B | $-61.9M | ||
| Q2 25 | $2.9B | $-70.9M | ||
| Q1 25 | $2.6B | $6.1M | ||
| Q4 24 | $2.2B | $-51.2M | ||
| Q3 24 | $2.5B | $-59.6M | ||
| Q2 24 | $3.0B | $-53.0M |
毛利率AXPRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% |
营业利润率AXPRGNX
| Q1 26 | — | — | ||
| Q4 25 | 28.2% | -190.0% | ||
| Q3 25 | 36.7% | -176.3% | ||
| Q2 25 | 34.4% | -296.3% | ||
| Q1 25 | 34.6% | 13.6% | ||
| Q4 24 | 27.7% | -242.1% | ||
| Q3 24 | 33.0% | -256.6% | ||
| Q2 24 | 38.6% | -251.3% |
净利率AXPRGNX
| Q1 26 | 15.7% | — | ||
| Q4 25 | 22.5% | -221.3% | ||
| Q3 25 | 27.9% | -208.3% | ||
| Q2 25 | 28.0% | -331.8% | ||
| Q1 25 | 26.8% | 6.8% | ||
| Q4 24 | 21.8% | -241.3% | ||
| Q3 24 | 25.8% | -246.3% | ||
| Q2 24 | 30.7% | -237.7% |
每股收益（稀释后）AXPRGNX
| Q1 26 | — | — | ||
| Q4 25 | $3.52 | $-1.30 | ||
| Q3 25 | $4.14 | $-1.20 | ||
| Q2 25 | $4.08 | $-1.38 | ||
| Q1 25 | $3.64 | $0.12 | ||
| Q4 24 | $3.04 | $-0.99 | ||
| Q3 24 | $3.49 | $-1.17 | ||
| Q2 24 | $4.15 | $-1.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | $60.4M | — |
| 股东权益账面价值 | $34.0M | $102.7M |
| 总资产 | $308.9M | $453.0M |
| 负债/权益比越低杠杆越低 | 1.78× | — |
8季度趋势，按日历期对齐
现金及短期投资AXPRGNX
| Q1 26 | — | — | ||
| Q4 25 | $742.0M | $230.1M | ||
| Q3 25 | $1.3B | $274.2M | ||
| Q2 25 | $197.0M | $323.3M | ||
| Q1 25 | $261.0M | $267.9M | ||
| Q4 24 | $221.0M | $234.7M | ||
| Q3 24 | $120.0M | $255.5M | ||
| Q2 24 | $188.0M | $290.4M |
总债务AXPRGNX
| Q1 26 | $60.4M | — | ||
| Q4 25 | $56.4B | — | ||
| Q3 25 | $57.8B | — | ||
| Q2 25 | $58.2B | — | ||
| Q1 25 | $51.2B | — | ||
| Q4 24 | $49.7B | — | ||
| Q3 24 | $53.5B | — | ||
| Q2 24 | $51.5B | — |
股东权益AXPRGNX
| Q1 26 | $34.0M | — | ||
| Q4 25 | $33.5B | $102.7M | ||
| Q3 25 | $32.4B | $161.5M | ||
| Q2 25 | $32.3B | $213.7M | ||
| Q1 25 | $31.2B | $274.2M | ||
| Q4 24 | $30.3B | $259.7M | ||
| Q3 24 | $29.7B | $301.4M | ||
| Q2 24 | $29.5B | $348.3M |
总资产AXPRGNX
| Q1 26 | $308.9M | — | ||
| Q4 25 | $300.1B | $453.0M | ||
| Q3 25 | $297.6B | $525.2M | ||
| Q2 25 | $295.6B | $581.0M | ||
| Q1 25 | $282.2B | $490.9M | ||
| Q4 24 | $271.5B | $466.0M | ||
| Q3 24 | $271.0B | $519.1M | ||
| Q2 24 | $272.2B | $569.4M |
负债/权益比AXPRGNX
| Q1 26 | 1.78× | — | ||
| Q4 25 | 1.68× | — | ||
| Q3 25 | 1.78× | — | ||
| Q2 25 | 1.80× | — | ||
| Q1 25 | 1.64× | — | ||
| Q4 24 | 1.64× | — | ||
| Q3 24 | 1.80× | — | ||
| Q2 24 | 1.74× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流AXPRGNX
| Q1 26 | — | — | ||
| Q4 25 | $3.1B | $-52.3M | ||
| Q3 25 | $6.2B | $-56.0M | ||
| Q2 25 | $4.4B | $-49.3M | ||
| Q1 25 | $4.8B | $33.6M | ||
| Q4 24 | $5.8B | $-31.6M | ||
| Q3 24 | $-1.8B | $-40.5M | ||
| Q2 24 | $4.5B | $-45.5M |
自由现金流AXPRGNX
| Q1 26 | — | — | ||
| Q4 25 | $2.3B | $-52.8M | ||
| Q3 25 | $5.6B | $-56.5M | ||
| Q2 25 | $3.7B | $-49.7M | ||
| Q1 25 | $4.3B | $32.6M | ||
| Q4 24 | $5.3B | $-32.7M | ||
| Q3 24 | $-2.3B | $-40.9M | ||
| Q2 24 | $4.0B | $-46.0M |
自由现金流率AXPRGNX
| Q1 26 | — | — | ||
| Q4 25 | 21.4% | -174.0% | ||
| Q3 25 | 53.6% | -189.9% | ||
| Q2 25 | 36.3% | -232.8% | ||
| Q1 25 | 45.0% | 36.6% | ||
| Q4 24 | 53.1% | -154.2% | ||
| Q3 24 | -23.3% | -168.9% | ||
| Q2 24 | 40.4% | -206.2% |
资本支出强度AXPRGNX
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | 1.7% | ||
| Q3 25 | 6.3% | 1.7% | ||
| Q2 25 | 6.0% | 1.8% | ||
| Q1 25 | 4.5% | 1.2% | ||
| Q4 24 | 5.0% | 5.1% | ||
| Q3 24 | 4.7% | 1.3% | ||
| Q2 24 | 5.8% | 2.1% |
现金转化率AXPRGNX
| Q1 26 | — | — | ||
| Q4 25 | 1.25× | — | ||
| Q3 25 | 2.15× | — | ||
| Q2 25 | 1.51× | — | ||
| Q1 25 | 1.84× | 5.53× | ||
| Q4 24 | 2.66× | — | ||
| Q3 24 | -0.72× | — | ||
| Q2 24 | 1.50× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AXP
| Discount revenue | $9.5M | 50% |
| Other | $8.9M | 47% |
| Deposits with banks and other | $512.0K | 3% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
